Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 3
2000 4
2002 2
2004 2
2005 3
2006 2
2008 2
2009 4
2010 5
2011 3
2012 3
2013 4
2014 2
2017 3
2019 3
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition.
Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, Coskran TM, Maresca KP, Keliher EJ, Yates PD, Kim AM, Kalgutkar AS, Buckbinder L. Roth Flach RJ, et al. Among authors: maresca kp. PLoS One. 2019 Mar 19;14(3):e0214150. doi: 10.1371/journal.pone.0214150. eCollection 2019. PLoS One. 2019. PMID: 30889221 Free PMC article.
First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.
Wakabayashi Y, Stenkrona P, Arakawa R, Yan X, Van Buskirk MG, Jenkins MD, Santamaria JAM, Maresca KP, Takano A, Liow JS, Chappie TA, Varrone A, Nag S, Zhang L, Hughes ZA, Schmidt CJ, Doran SD, Mannes A, Zanotti-Fregonara P, Ooms M, Morse CL, Zoghbi SS, Halldin C, Pike VW, Innis RB. Wakabayashi Y, et al. Among authors: maresca kp. J Nucl Med. 2022 Dec;63(12):1919-1924. doi: 10.2967/jnumed.122.263838. Epub 2022 Jun 30. J Nucl Med. 2022. PMID: 35772961 Free PMC article.
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates.
Arakawa R, Takano A, Nag S, Jia Z, Amini N, Maresca KP, Zhang L, Keliher EJ, Butler CR, Piro JR, Samad TA, Smith D, Nason D, O'Neil S, Trapa P, Fonseca KR, Litchfield J, McCarthy T, Carson RE, Halldin C. Arakawa R, et al. Among authors: maresca kp. EJNMMI Res. 2022 Mar 4;12(1):13. doi: 10.1186/s13550-022-00882-2. EJNMMI Res. 2022. PMID: 35244788 Free PMC article.
Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.
Chin BB, Kronauge JF, Femia FJ, Chen J, Maresca KP, Hillier S, Petry NA, James OG, Oldan JD, Armor T, Stubbs JB, Stabin MG, Babich JW. Chin BB, et al. Among authors: maresca kp. J Nucl Med. 2014 May;55(5):765-71. doi: 10.2967/jnumed.113.124057. Epub 2014 Mar 13. J Nucl Med. 2014. PMID: 24627436 Free article. Clinical Trial.
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.
McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C. McClure KF, et al. Among authors: maresca k. Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16218-16222. doi: 10.1002/anie.201708744. Epub 2017 Nov 24. Angew Chem Int Ed Engl. 2017. PMID: 29073340
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET.
Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH, Waterhouse RN, Vasdev N. Collier TL, et al. Among authors: maresca kp. Mol Imaging. 2017 Jan-Dec;16:1536012117736669. doi: 10.1177/1536012117736669. Mol Imaging. 2017. PMID: 29067878 Free PMC article.
46 results